Skip to main content

Table 3 The relationship of patients’ clinicopathological characteristics and somatic mutations with progression free survival and overall survival

From: Identification and clinical significance of somatic oncogenic mutations in epithelial ovarian cancer

 

N

3-Year RFS (%)

P-value

3-Year OS (%)

P-value

Age (years)

  

0.17

 

0.31

 < 60

38

55.3

 

78.9

 

 ≥ 60

42

45.2

 

71.4

 

Stage

  

< 0.001

 

< 0.001

 I/II

34

79.4

 

93.9

 

 III/IV

46

28.3

 

63.0

 

Histology

  

< 0.001

 

0.072

 SC

32

17.9

 

67.9

 

 CCC

21

47.6

 

61.9

 

 EC

20

80

 

85.0

 

 MC

7

87.5

 

100

 

TP53

  

0.088

 

0.74

 WT

45

57.8

 

75.6

 

 MT

35

31.4

 

74.3

 

PIK3CA

  

0.047

 

0.74

 WT

58

43.1

 

75.9

 

 MT

22

68.2

 

72.7

 

KRAS

  

0.043

 

0.11

 WT

61

44.2

 

72.1

 

 MT

19

68.4

 

84.2

 

PTEN

  

0.58

 

0.84

 WT

72

48.6

 

75.0

 

 MT

8

62.5

 

75.0

 

CTNNB1

  

0.59

 

0.89

 WT

72

48.6

 

75.0

 

 MT

8

62.5

 

75.0

 
  1. SC Serous carcinoma, EM Endometrioid carcinoma, CCC Clear cell carcinoma, MC Mucinous carcinoma, WT Wild-type, MT Mutant
Back to article page

Journal of Ovarian Research

ISSN: 1757-2215

Contact us